With sales of its lead product booming – up by 51% in 2018 – the Pharming Group NV produced its first annual net profit since its founding in 1988.
Revenue from product sales rose to €134.3 million in 2018 from a restated €88.7 million in 2017 while net profit came to €24.9 million compared with a loss of €76.2 million in 2017.
Making this happen was a boom in sales of Ruconest, the company’s product for the treatment of hereditary angioedema (HAE), a condition that is estimated to affect up to 10,000 people in the US alone.